Private Capital Advisors Inc. Invests $13.75 Million in Guardant Health, Inc. (NASDAQ:GH)

Private Capital Advisors Inc. purchased a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 322,818 shares of the company's stock, valued at approximately $13,752,000. Guardant Health accounts for about 1.6% of Private Capital Advisors Inc.'s investment portfolio, making the stock its 19th largest position. Private Capital Advisors Inc. owned 0.26% of Guardant Health at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GH. Janney Montgomery Scott LLC purchased a new stake in shares of Guardant Health in the first quarter worth $232,000. Stifel Financial Corp grew its stake in shares of Guardant Health by 25.1% in the fourth quarter. Stifel Financial Corp now owns 49,927 shares of the company's stock worth $1,525,000 after acquiring an additional 10,006 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Guardant Health in the fourth quarter worth $2,211,000. Teacher Retirement System of Texas purchased a new stake in shares of Guardant Health in the first quarter worth $866,000. Finally, Fifth Third Bancorp purchased a new stake in shares of Guardant Health in the first quarter worth $279,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Myrtle S. Potter sold 2,626 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $49.70, for a total value of $130,512.20. Following the sale, the director directly owned 18,180 shares in the company, valued at approximately $903,546. This represents a 12.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Meghan V. Joyce sold 3,337 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The stock was sold at an average price of $47.22, for a total transaction of $157,573.14. Following the sale, the director directly owned 11,150 shares of the company's stock, valued at approximately $526,503. The trade was a 23.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 342,158 shares of company stock valued at $17,075,394 in the last quarter. 6.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on GH shares. Stephens reissued an "overweight" rating and issued a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. TD Securities increased their target price on Guardant Health from $56.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Barclays increased their target price on Guardant Health from $55.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday, May 1st. Evercore ISI raised Guardant Health to a "strong-buy" rating in a report on Monday. Finally, Canaccord Genuity Group increased their target price on Guardant Health from $60.00 to $65.00 and gave the company a "buy" rating in a report on Thursday, May 1st. Twenty-one investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $53.76.

Guardant Health Trading Down 1.1%

NASDAQ:GH traded down $0.53 during trading hours on Thursday, hitting $47.28. 2,864,426 shares of the stock traded hands, compared to its average volume of 2,174,541. The firm has a 50 day moving average price of $46.21 and a 200 day moving average price of $44.17. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $53.42. The firm has a market cap of $5.86 billion, a price-to-earnings ratio of -13.95 and a beta of 1.44.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The firm had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. During the same quarter last year, the company earned ($0.46) earnings per share. The firm's revenue was up 20.8% on a year-over-year basis. Research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.